NCT00880074

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

Early Prediction of Clinical Response to Chemotherapy With FLT-PET

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial studies fluorine F-18 fluorothymidine (FLT)-positron emission tomography (PET) in predicting response to chemotherapy in patients with advanced malignancies. FLT solution can help locate cancer cells inside the body. Diagnostic procedures, such as FLT-PET, may help find tumors and measure a patient's response to treatment.

Detailed description

PRIMARY OBJECTIVES: I. To determine if concurrent treatment with temsirolimus and bevacizumab demonstrates a dose-dependent decrease in FLT-PET standardized uptake value which correlates with clinical response. SECONDARY OBJECTIVES: I. To determine the relationship between FLT-PET and markers of angiogenesis and drug activity in tumor biopsy, along with surrogate peripheral blood markers of target inhibition and drug activity. OUTLINE: Patients undergo fluorine F-18 fluorothymidine PET at baseline, at day 6-8 of course 1, day 20 of course 2, and prior to day 1 of course 3.

Conditions

• Malignant Neoplasm

Interventions

Type	Name	Description
DRUG	Fluorothymidine F-18	Undergo fluorine F-18 fluorothymidine PET
OTHER	Laboratory Biomarker Analysis	Optional correlative studies
PROCEDURE	Positron Emission Tomography	Undergo fluorine F-18 fluorothymidine PET

Timeline

• Start date: 2009-04-09
• Primary completion: 2022-02-04
• Completion: 2022-02-04
• First posted: 2009-04-13
• Last updated: 2023-06-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study